Details

Autor(en) / Beteiligte

• Mannis, Gabriel N
• Martin, 3rd, Thomas G
• Damon, Lloyd E
• Logan, Aaron C
• Olin, Rebecca L
• Flanders, Michael D
• Ai, Weiyun Z
• Gaensler, Karin M L
• Kaplan, Lawrence D
• Sayre, Peter H
• Smith, Catherine C
• Wolf, Jeffrey L
• Andreadis, Charalambos

Titel

Long-term outcomes of patients with intermediate-risk acute myeloid leukemia treated with autologous hematopoietic cell transplant in first complete remission

Ist Teil von

• Leukemia & lymphoma, 2016-07, Vol.57 (7), p.1560-1566

Ort / Verlag

United States

Erscheinungsjahr

2016

Quelle

MEDLINE

Beschreibungen/Notizen

• In 2014, autologous hematopoietic cell transplant (autoHCT) was removed from the National Comprehensive Cancer Network guidelines as a recommended treatment for patients with intermediate-risk AML in first complete remission (CR1). We reviewed the outcomes of all patients with intermediate-risk AML treated with autoHCT in CR1 at our institution. Of 334 patients who underwent autoHCT for AML between 1988 and 2013, 133 patients with intermediate-risk AML in CR1 were identified. Cytogenetics were diploid in 97 (73%). With a median follow-up of 4.1 years (range 0.1-17), median overall survival (OS) is 6.7 years; at 5 years post-transplant, 59% of patients remain alive and 43% remain relapse-free. Forty-eight percent of relapsing patients proceeded to salvage alloHCT. Our findings demonstrate that nearly half of patients with intermediate-risk AML in CR1 achieve sustained remissions, and that salvage alloHCT is feasible in those who relapse. AutoHCT therefore remains a reasonable option for intermediate-risk patients with AML in CR1.